Immune thrombocytopenia associated with efalizumab therapy for psoriasis [7]

Annals of Internal Medicine

Volumn 143, Issue 10, 2005, Pages 761-763

  Warkentin, Theodore E ^a   Kwon, Paul ^b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EFALIZUMAB; IMMUNOGLOBULIN G ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RHESUS D ANTIBODY; VALPROIC ACID;

CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; FLOW CYTOMETRY; HUMAN; LETTER; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MUCOSAL BLEEDING; PETECHIA; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 28044440284     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-10-200511150-00028     Document Type: Letter

References (4)

1. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003; 349:2004-13. [PMID: 14627785]
2. Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther. 2003;45: 97-8. [PMID: 14657802]
3. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129:886-90. [PMID: 9867731]
4. Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966-74. [PMID: 12956768]